Published in Vaccine Weekly, August 16th, 1999
Results of a U.S. Phase II, multicenter, randomized, placebo-controlled clinical trial indicated that after two doses the live attenuated human rotavirus vaccine - dubbed 89-12 - was 89 percent effective with a 95% confidence interval (CI) of 65.4-94.5 percent.
The current reassortant tetravalent vaccine, based on rhesus rotavirus, after three doses is 49 to 68 percent effective in developed countries.
"The efficacy reported in this study (89 percent against any rotavirus illness) is the highest reported for any...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.